Mycophenolate Mofetil

Introduction Overview

Generic Name

mycophenolate mofetil

Brand Name

Cellcept

Dosage Form

Oral: Capsule, Tablet, Powder for Suspension

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Mycophenolate mofetil (MMF) is a prodrug that is rapidly absorbed following oral administration. After ingestion, MMF is hydrolyzed by esterases in the gastrointestinal tract, blood, and liver to its active metabolite, mycophenolic acid (MPA). The bioavailability of MPA from MMF capsules or tablets is approximately 94%, with peak plasma concentrations occurring 1 to 2 hours post-dose. Food intake can delay the time to peak concentration and reduce the extent of absorption; thus, the drug is typically recommended to be taken on an empty stomach - 1 hour before or 2 hours after meals. MMF shows dose-proportional pharmacokinetics in the therapeutic range but may saturate at higher doses.

Distribution:
MPA is extensively bound to plasma albumin (97-99%), which limits its free, pharmacologically active fraction. The volume of distribution is approximately 38–45 L, indicating distribution beyond the vascular compartment. The drug crosses the placenta and is excreted in breast milk, and distribution into other tissues occurs but is quantitatively limited by protein binding. The extensive binding affects the pharmacodynamics and potential drug interactions, especially with drugs altering albumin levels or displacement.

Metabolism:
MPA undergoes extensive hepatic metabolism primarily via uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, notably UGT1A9 and UGT2B7, converting it to the inactive 7-O-glucuronide metabolite (MPAG). This metabolite circulates at higher plasma concentrations than MPA but lacks immunosuppressive activity. Enterohepatic recirculation of MPA occurs as MPAG is excreted into the bile, hydrolyzed by gut flora, and reabsorbed as active MPA, contributing to a second plasma concentration peak several hours post-dose. Interindividual variability in UGT activity and gut flora composition can impact plasma levels and clinical response.

Elimination:
The elimination of MPA occurs mainly via renal excretion of MPAG. Approximately 87% of the administered MMF dose is recovered in urine, mostly as MPAG; less than 5% is excreted unchanged as MPA. The elimination half-life of MPA is approximately 16 to 18 hours when administered twice daily, influenced by enterohepatic recycling. Renal impairment can reduce clearance of MPAG, leading to accumulation, while hepatic impairment may alter metabolism, necessitating cautious dosing and monitoring in these populations. Mycophenolate mofetil is not significantly removed by dialysis.

Dosage Forms

Available Dosage Forms:
Mycophenolate mofetil is available in the following oral formulations:
- Capsules
- Tablets
- Powder for Suspension (oral liquid)

Dosages for Adults and Adolescents:
- For adults receiving a heart transplant: 1.5 grams twice daily (capsules, tablets, or suspension).
- For adults receiving a kidney transplant: 1 gram twice daily (capsules, tablets, or suspension).
- For adults receiving a liver transplant: 1.5 grams twice daily.
- Delayed-release tablets are indicated for adults preventing kidney transplant rejection at a dose of 720 mg twice daily.

Specific Patient Populations:
- Pediatric patients:
* Kidney transplantation: Capsules, suspension, or tablets are used, with dose adjustment based on body surface area (BSA). Suspension dosing: 600 mg/m² twice daily; capsules/tablets: 750 mg to 1 g twice daily for children ≥3 months.
* Delayed-release tablets in children ≥5 years, at least 6 months post-kidney transplant: 400 mg/m² twice daily, not exceeding 720 mg twice daily.
* Safety and efficacy not established in infants <3 months or children <5 years (for delayed-release tablets).
- Geriatric patients: No specific dose adjustments required, but monitoring advised due to possible age-related renal or hepatic impairment.

Detailed Dosing Notes:
- Capsules, tablets, and suspension should be swallowed whole, not chewed, crushed, or opened.
- Oral suspension must be measured with an appropriate oral dispenser; do not mix with other medications.
- Take on an empty stomach, 1 hour before or 2 hours after meals for optimal absorption.
- If antacids containing aluminum or magnesium are used, space administration by at least 2 hours after MMF.
- Dose adjustments should be individualized based on tolerance, renal function, and concomitant immunosuppressants.

Mechanism Of Action

Mycophenolate mofetil is an immunosuppressant prodrug that is hydrolyzed in vivo to mycophenolic acid (MPA), its pharmacologically active form. MPA selectively inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme critical for de novo guanine nucleotide synthesis in lymphocytes. This selective inhibition impairs the proliferation of T and B lymphocytes, which rely heavily on this pathway due to limited salvage pathways, thus reducing immune responses.

At the molecular level, MPA induces reversible, noncompetitive inhibition of IMPDH types I and II, with higher affinity for type II predominantly expressed in activated lymphocytes. This leads to depletion of guanosine nucleotides, inhibiting DNA synthesis and suppressing the proliferation of both T and B cells, which are essential mediators of transplant rejection.

Beyond lymphocyte proliferation inhibition, MPA affects glycosylation of adhesion molecules, thus impairing the recruitment and trafficking of immune cells, as well as antibody formation and the generation of cytotoxic lymphocytes. This multifaceted immunomodulation helps prevent organ rejection post-transplantation.

Comparatively, unlike calcineurin inhibitors (cyclosporine, tacrolimus) that affect T-cell activation through calcium-dependent pathways, MPA targets nucleotide synthesis, offering a complementary mechanism for immunosuppression. Clinical trials have demonstrated its efficacy and better tolerability, especially in combination therapy for organ transplant recipients. Research continues to explore MPA’s impact on various immune-mediated disorders and its role in reducing rejection rates with fewer nephrotoxic effects.

Pharmacological Actions

Selective inhibition of inosine monophosphate dehydrogenase (IMPDH) leading to suppressed lymphocyte proliferation.
Immunosuppressive effect primarily on activated T and B lymphocytes critical in graft rejection.
Reversible, noncompetitive inhibition of guanine nucleotide synthesis essential for DNA replication in immune cells.
Reduction of antibody formation and cytotoxic T-lymphocyte activity.
Modification of glycoprotein synthesis affecting cell adhesion and migration of immune cells.
Complementary immunosuppressive mechanism to calcineurin inhibitors with reduced nephrotoxicity.
Ability to reduce immune responses involved in transplant organ rejection.
Potential antiviral effects against some opportunistic infections by altering lymphocyte function.
Inhibition of cytotoxic lymphocyte-induced tissue injury.
Exhibition of anti-inflammatory properties contributing to reduction in immune-mediated organ damage.

Therapeutic Or Clinical Uses

Prevention of organ rejection in kidney transplant recipients.
Prevention of organ rejection in heart transplant recipients.
Prevention of organ rejection in liver transplant recipients.
Immunosuppressive therapy in combination with cyclosporine and corticosteroids.
Management of autoimmune conditions off-label based on immunosuppressive properties.
Reduction of graft-versus-host disease risk post hematopoietic stem cell transplantation (off-label).
Alternative therapy in patients intolerant to other immunosuppressants.
Used to lower dosage requirements and toxicity of calcineurin inhibitors in transplant regimens.
Part of maintenance immunosuppressive regimens post-organ transplantation.
Potential investigational use in certain autoimmune and inflammatory diseases.

Side Or Adverse Effects

Gastrointestinal disturbances including nausea, vomiting, diarrhea, and abdominal pain.
Leukopenia and neutropenia increasing risk of infections.
Anemia and pure red cell aplasia manifesting as severe anemia.
Increased susceptibility to opportunistic infections including cytomegalovirus and BK virus nephropathy.
Increased risk of malignancies, particularly lymphoma and skin cancers.
Hypertension and peripheral edema associated with fluid retention.
Headache, dizziness, and tremors affecting neurological function.
Increased risk of severe infections with potential fatal outcomes.
Skin reactions including rash and pruritus.
Respiratory symptoms such as cough and hoarseness.
Elevated liver enzymes indicating potential hepatotoxicity.
Increased risk of progressive multifocal leukoencephalopathy (PML).
Potential reactivation of hepatitis B or C infections.
Renal impairment exacerbation in susceptible individuals.
Rare occurrences of severe allergic reactions and serum sickness-like symptoms.

Precautions

Pregnancy avoidance due to high risk of first trimester pregnancy loss and congenital malformations.
Mandatory counseling on pregnancy prevention and use of two reliable contraception methods.
Avoid breastfeeding during treatment due to potential harm to infants.
Monitor blood cell counts regularly to detect leukopenia or anemia early.
Close monitoring for signs of infection; avoid exposure to sick individuals.
Caution in patients with pre-existing bone marrow suppression or hepatic impairment.
Adjust dosage carefully in patients with severe renal impairment.
Avoid live vaccines during and shortly after treatment due to immunosuppression.
Careful handling to prevent exposure to drug powder; wash skin thoroughly if contact occurs.
Observe strict adherence to dosing schedule to prevent transplant rejection.
Use sunscreen and protective clothing to reduce risk of skin cancer.
Avoid abrupt discontinuation to reduce risk of acute graft rejection.
Screen for hepatitis B and C before initiating therapy and monitor for reactivation.
Patients with rare genetic disorders like Kelley-Seegmiller or Lesch-Nyhan syndrome should avoid use.
Use cautiously in patients with gastrointestinal ulceration or bleeding tendency.

Warnings

High risk of embryofetal toxicity and congenital malformations; contraindicated in pregnancy unless no alternatives.
Potential development of lymphoproliferative disorders and other malignancies.
Increased susceptibility to serious and opportunistic infections including viral, bacterial, and fungal etiologies.
Risk of progressive multifocal leukoencephalopathy (PML), a fatal brain infection.
Possibility of pure red cell aplasia causing severe anemia.
Reactivation of hepatitis B or C with attendant serious hepatic consequences.
Severe gastrointestinal bleeding and ulceration reported; monitor for signs such as black stools or vomiting blood.
Avoid live vaccines during treatment due to suppressed immune response and risk of vaccine-associated disease.
Potential for drug accumulation and toxicity in renal or hepatic impairment.
Risk of graft rejection if therapy is interrupted or discontinued abruptly.
Cautious use in patients with prior history of malignancy or predisposition to skin cancer.
May cause teratogenic effects in men; sperm donation should be avoided during and after therapy.
Patients should be advised to report any unusual neurological symptoms promptly.
Risk of infection may be exacerbated by concomitant use of other immunosuppressants.
Use with other medicines that interfere with absorption or metabolism may require dosage adjustment.

Contraindication

Known hypersensitivity to mycophenolate mofetil or mycophenolic acid.
Pregnancy unless no safer alternatives are available due to teratogenicity.
Patients with rare genetic diseases Kelley-Seegmiller syndrome or Lesch-Nyhan syndrome.
Active severe infections such as systemic bacterial, viral, or fungal infections.
Patients with severe gastrointestinal bleeding or ulcers at baseline.
Hypersensitivity or allergy to any component of the formulation, including excipients.
Use with live vaccines during therapy.
Severe bone marrow suppression or baseline neutropenia before initiation.
Concurrent administration with drugs that markedly reduce absorption or increase toxicity without dose adjustment.
Known intolerance to oral suspension containing aspartame in patients with phenylketonuria (PKU).
Use in infants below age limits where safety has not been established (e.g., <3 months for certain forms).
Pre-existing progressive multifocal leukoencephalopathy (PML) or demyelinating diseases.
Severe hepatic impairment without close monitoring and careful dose evaluation.
Patients unable to adhere to strict contraceptive measures or monitoring requirements.

Drug Interactions

Concomitant use with cyclosporine may reduce mycophenolate bioavailability; dosing adjustments may be necessary.
Azathioprine co-administration increases risk of bone marrow suppression.
Antacids containing aluminum or magnesium can reduce absorption; separate administration by at least 2 hours.
Proton pump inhibitors (e.g., omeprazole, lansoprazole) may decrease mycophenolate absorption.
Antibiotics like ciprofloxacin may alter gut flora and reduce enterohepatic recirculation of MPA.
Cholestyramine and colestipol bind MPA metabolites, lowering circulating levels and efficacy.
Iron, lanthanum carbonate, and sevelamer may reduce mycophenolate absorption causing decreased effectiveness.
Live vaccines contraindicated due to immunosuppression and risk of infection.
Tacrolimus co-administration requires monitoring for increased immunosuppression and infection risk.
Metronidazole may interact, potentially altering mycophenolate metabolism or gut flora.
Co-administration with certain hormonal contraceptives (e.g., desogestrel, ethinyl estradiol) may reduce contraceptive efficacy.
Rifampin may induce metabolism reducing efficacy of mycophenolate.
Drugs affecting UGT enzymes or enterohepatic circulation may alter MPA plasma levels.
Concomitant use with vaccines (various live viral vaccines) should be avoided.
Use with immunomodulators like azathioprine or sirolimus may increase risk of cytopenias and infections.

Preparations Of The Drug

Capsules typically dosed at 250 mg and 500 mg strengths.
Tablets: immediate-release and delayed-release formulations; delayed-release tablets dosed at 360 mg and 720 mg strengths.
Powder for oral suspension available with specific concentrations for pediatric dosing.
Oral suspension contains aspartame (phenylalanine), requiring caution in patients with PKU.
Formulations provided for precise dosing adjustments in pediatric and adult patients based on body surface area.
Commercial brands include Cellcept and Myhibbin.
Packaging ensures protection from moisture and light; suspension should be refrigerated and discarded after 60 days.
Oral solid forms should be swallowed whole; capsules not to be opened or crushed to prevent exposure.
Dosage forms accompanied by patient Medication Guides outlining handling and administration precautions.
Powder for suspension includes measuring devices for accurate dosing.
Formulations may differ slightly in excipients influencing tolerability and administration.
Dosage forms designed to optimize absorption and minimize GI irritation.
Available in various package sizes for inpatient and outpatient use.
Strict quality control ensures batch uniformity and stability over shelf life.